Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female outpatients over 20years of age~2. patients confirmed to have PAD~   * ABI ≤0.9~  * Occlusion rate\>50%~3. LE PAD with Fontaine stage II/III~4. LE pain VAS≥40mm at screening~Exclusion Criteria:~1. Patients who underwent vascular surgery or endovascular procedure for PAD within 1month prior to study. Patients who need vascular surgery or endovascular procedure for PAD during this study also should be excluded.~2. Patients with peripheral neuropathy.~3. Patients with ischemic heart diseases or underwent percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months prior to study.~4. Patients who has diagnosed cerebrovascular diseases within 6 months prior to study.~5. Patients with hemorrhage or predisposition to hemorrhage at screening visit.~6. Uncontrolled hypertension defined as ≥ 180 mmHg of systolic blood pressure or ≥ 110 mmHg of diastolic blood pressure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SID142 (Type: EXPERIMENTAL): Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
- Rinexin® Tab (Type: ACTIVE_COMPARATOR): Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).